Skip to content

Protective Step Training in Parkinson's Disease

Protective Step Training in People With Parkinson's Disease and Postural Disturbances

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03895814
Enrollment
35
Registered
2019-03-29
Start date
2019-06-01
Completion date
2022-06-01
Last updated
2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Balance, Falls, Posture, Cognition, Training

Brief summary

The primary purpose of this project is to determine the preliminary effectiveness of protective step training to improve balance and reduce falls in people with Parkinson's disease (PD) and postural disturbances. A secondary purpose is to understand which baseline patient characteristics predict responsiveness to treatment. By informing 1) the effectiveness of a promising rehabilitative intervention, and 2) the selection of the participants that will be most responsive to treatment, these data may enhance clinicians' ability to treat balance disturbances in people with PD. Importantly, protective step training, described in this proposal, can be quickly deployed in the clinic at minimal cost. Therefore, if shown to be effective via this and subsequent trials, this approach can be easily integrated into care, immediately impacting a large number of people with PD.

Detailed description

This project contains 3 aims: Aims 1 and 2 address the primary goal of this project: Determining the effectiveness of protective step training. Aim 1 will test whether perturbation training can improve protective stepping in people with PD with postural dysfunction. Aim 2 will test whether improvements are retained over 2 months and generalize to untrained perturbation tasks (which may be important for real world situations). Importantly, investigators will also gather exploratory data regarding the effect of perturbation training on falls. Aim 3 addresses the secondary goal of this project: Determining for whom protective step training is most beneficial. Aim 3 will relate behavioral factors and neuroimaging outcomes to the magnitude of improvement in protective stepping. All aims will be tested in people with PD who have postural disturbances. To complete these aims, participants will undergo 12 visits to the laboratory over the course of about 5 months. These will include 6 training visits over the course of 2 weeks, surrounded by 6 assessment visits before and after the training. During assessment visits, investigators will assess the ability to step quickly in response to a loss of balance (e.g. a slip), as well as thinking assessments and, if eligible, investigators will complete an MRI. During training visits, investigators will train the ability to step quickly in response to a slip. In this study, participants will serve as their own controls. As such, there is no randomization to multiple groups.

Interventions

Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.

Sponsors

University of Utah
CollaboratorOTHER
Colorado State University
CollaboratorOTHER
Arizona State University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

The single-group assessment prohibits participant/outcomes masking.

Intervention model description

Multi-baseline assessment

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Neurologist diagnosed PD * Postural Instability / Gait Dysfunction (PIGD) * Ability to stand unaided for 5 minutes

Exclusion criteria

* non-PD related neurological pathology * orthopedic impairments affecting balance

Design outcomes

Primary

MeasureTime frameDescription
Stepping performance, measured as Margin of Stability (MOS)Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)MOS: Distance between the extrapolated center of mass and base of support at first foot contact after the slip

Secondary

MeasureTime frameDescription
Stepping performance, measured as First Step LatencyChange across baseline period (2 weeks), compared to change across intervention period (2 weeks)Step Latency: Time taken to lift the foot off the ground after the slip start
Stepping performance, measured as First Step LengthChange across baseline period (2 weeks), compared to change across intervention period (2 weeks)Step Length: Length of the first step after the slip
Cognition, measured as the total score on the SCales for Outcomes in PArkinson's disease-COGnition (SCOPA-COG)BaselineSCOPA-COG: This scale characterizes cognitive capacity of several domains, and was developed specifically for people with PD. Range: 0-43 (higher score reflects better cognitive capacity). Subscales/domains are calculated, and the \*total\* score is calculated as the sum of each subscale.
Structural brain connectivity between the cortex (supplementary motor area), and basal ganglia (striatum)BaselineDiffusion Tensor Imaging data (collected via MRI), will be collected and analyzed to characterize the structural connectivity specifically between the cortex and basal ganglia.

Other

MeasureTime frameDescription
Fall frequencyChange in the number of falls during baseline (2 months) and follow-up (2 months) periods.Number of falls will be recorded via fall calendar in the 2 month period prior to training (baseline) and the 2 month period following training (post)
Generalization of stepping improvement (measured as Margin of Stability; MOS)Change in MOS score from Baseline 2 to Post (2 weeks between collections)Characterize whether training impacts MOS of an untrained reactive stepping task
Retention of stepping improvement (measured as Margin of Stability; MOS) over 2 monthsChange in MOS score from Baseline to Follow-up (10 weeks between collections)Characterization of whether MOS changes observed over training period are retained at follow-up.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026